Myelodysplastic Syndrome (MDS)

What Is Myelodysplastic Syndrome (MDS)?

Myelodysplastic syndrome (MDS) is a group of blood disorders in which the bone marrow does not produce enough healthy, functional blood cells. Instead of maturing normally, blood cells develop abnormally — a process called dysplasia — and many are destroyed before they ever leave the bone marrow. The result is a shortage of one or more types of blood cells: red blood cells, white blood cells, or platelets.

MDS is not a single disease but a spectrum of related conditions ranging from low-risk forms that progress slowly over many years to high-risk forms that can transform into acute myeloid leukemia (AML). The course of MDS varies widely — many people have slow-growing forms that can be monitored and managed for years. Understanding where on this spectrum a person's MDS falls is one of the most important parts of diagnosis and treatment planning.

MDS is primarily a disease of older adults, with most diagnoses occurring after age 65. It is slightly more common in men than women. In most people, MDS is not passed down in families.

Important: This article is for general educational purposes only and does not replace personalized medical advice from your healthcare provider. Always discuss your diagnosis and treatment options with your doctor.

Key Facts About MDS

MDS is a bone marrow disorder that causes low counts of one or more blood cell types
It is most common in adults over 65
MDS ranges from slow-growing, low-risk forms to more aggressive types with a risk of transforming into leukemia
Treatment depends on disease risk, age, overall health, and blood count severity
Regular blood test monitoring is a central part of managing MDS

How the Bone Marrow Is Affected

In healthy bone marrow, stem cells develop into mature, fully functional red blood cells, white blood cells, and platelets. In MDS, genetic mutations in bone marrow stem cells disrupt this process. The abnormal cells either fail to mature properly or are destroyed prematurely — a process called ineffective hematopoiesis.

The consequences depend on which cell lines are affected:

Low red blood cells (anemia): fatigue, pallor, shortness of breath
Low white blood cells (leukopenia), including low neutrophils): increased susceptibility to infections
Low platelets (thrombocytopenia): easy bruising and increased bleeding risk

In some people, all three cell lines are reduced — a condition called pancytopenia (low red cells, white cells, and platelets at the same time).

Types of MDS

The World Health Organization (WHO) classifies MDS into several subtypes based on the number of abnormal cell lines, the percentage of immature cells (blasts) in the bone marrow, and specific genetic features. Common subtypes include:

MDS With Single Lineage Dysplasia

Only one type of blood cell is affected — most commonly red blood cells. This is generally considered a lower-risk form.

MDS With Multilineage Dysplasia

Two or more cell types are affected. Associated with a higher risk of progression and more pronounced symptoms than single lineage disease.

MDS With Ring Sideroblasts

Abnormal red blood cells contain rings of iron deposits around the nucleus. Often associated with mutations in the SF3B1 gene and generally carries a more favorable prognosis.

MDS With Excess Blasts

The bone marrow contains 5–19% immature blast cells. This subtype carries a higher risk of transformation to acute myeloid leukemia (AML) and typically requires more active treatment.

MDS With Isolated Del(5q)

Caused by a deletion on chromosome 5. Associated with a good prognosis and responds well to a specific treatment (lenalidomide).

MDS, Unclassifiable

Cases that do not fit neatly into other categories.

Symptoms of MDS

Symptoms of MDS are largely determined by which blood cell lines are affected and how severely. Many people are diagnosed after a routine blood test shows unexpectedly low counts, before significant symptoms develop.

Symptoms Related to Low Red Blood Cells (Anemia)

Persistent fatigue or weakness
Shortness of breath with normal activity
Pallor (pale skin, pale gums, or pale inner eyelids)
Dizziness or lightheadedness
Rapid or irregular heartbeat

Symptoms Related to Low White Blood Cells

Frequent or unusually severe infections
Infections that take longer than normal to resolve
Fever without a clear cause

Symptoms Related to Low Platelets

Easy or unexplained bruising
Petechiae (tiny flat red or purple spots on the skin)
Prolonged bleeding from minor cuts
Bleeding gums or frequent nosebleeds
Heavy menstrual bleeding

When to Seek Medical Attention

Contact your doctor promptly if you experience unexplained fatigue that does not improve with rest, recurrent infections, unusual bruising or bleeding, or if you develop a fever or signs of infection — especially if you know your white blood cell count is low. If a blood test shows abnormally low counts in one or more cell lines, follow up with your doctor even if you feel well.

Causes and Risk Factors

MDS arises from acquired genetic mutations in bone marrow stem cells. These mutations are not inherited in most cases — they develop over time, and in many patients no specific cause is identified. Most cases cannot be clearly linked to a single preventable cause.

Known risk factors include:

Age: MDS is rare before age 50 and most common after age 65
Male sex: MDS affects men slightly more often than women
Previous chemotherapy: Certain chemotherapy drugs — particularly alkylating agents and topoisomerase II inhibitors — increase the risk of therapy-related MDS, which typically develops five to ten years after treatment
Previous radiation therapy: Especially radiation to large areas of bone marrow
Exposure to benzene or other industrial chemicals
Heavy tobacco smoking
Rare inherited syndromes: Conditions such as Fanconi anemia, dyskeratosis congenita, and Diamond-Blackfan anemia carry an elevated risk

Diagnosis

MDS is diagnosed through a combination of blood tests, bone marrow evaluation, and genetic testing. There is no single test that confirms MDS — the diagnosis requires integrating multiple findings.

Complete Blood Count (CBC)

The CBC is usually the first test to suggest MDS. Common findings include:

Low hemoglobin (anemia)
Low platelet count (thrombocytopenia)
Low white blood cell count (leukopenia)
Elevated Mean Corpuscular Volume (MCV): red blood cells that are larger than normal (macrocytosis) are common in MDS
Elevated Red Cell Distribution Width (RDW): reflecting variation in red blood cell size
Low Mean Platelet Volume (MPV): smaller platelets reflecting impaired platelet production
Abnormal counts in two or more cell lines (pancytopenia) in more advanced disease

Peripheral Blood Smear

A blood smear allows a hematologist to examine the shape, size, and appearance of blood cells directly under a microscope. Dysplastic features — such as abnormally shaped red blood cells, hypersegmented neutrophils, or abnormal platelets — may be visible.

Bone Marrow Biopsy and Aspiration

A bone marrow biopsy is essential to confirm MDS. It reveals:

The percentage of blast cells (immature cells) in the marrow
The degree of dysplasia across cell lines
Overall bone marrow cellularity

Cytogenetic and Molecular Testing

Chromosomal analysis (karyotyping) and genetic mutation testing are critical for classifying MDS and estimating prognosis. Common mutations include SF3B1, TET2, ASXL1, DNMT3A, and TP53. Specific chromosomal abnormalities — such as del(5q), monosomy 7, and complex karyotype — have important prognostic significance.

Risk Scoring

Once diagnosed, doctors use scoring systems such as the Revised International Prognostic Scoring System (IPSS-R) to estimate the risk of disease progression and guide treatment decisions. The IPSS-R groups MDS into very low, low, intermediate, high, or very high risk, which helps guide how intensive treatment should be. The score incorporates bone marrow blast percentage, number of cell lines affected, and cytogenetic findings.

Treatment

Treatment for MDS is guided by the patient's IPSS-R risk score, age, overall health, and treatment goals. Not all patients require immediate active treatment.

Watchful Waiting

For patients with low-risk MDS, stable blood counts, and no significant symptoms, active surveillance with regular CBC monitoring may be the appropriate initial approach. Some patients remain stable for years without requiring treatment.

Supportive Care

Supportive care aims to manage symptoms and maintain quality of life without targeting the underlying disease:

Red blood cell transfusions: For symptomatic anemia. Frequent transfusions can lead to iron overload over time, which may require iron chelation therapy.
Platelet transfusions: For serious bleeding episodes with very low platelet counts.
Growth factors: Erythropoiesis-stimulating agents (ESAs) such as erythropoietin can reduce the need for transfusions in some patients with low-risk MDS. They tend to work best when serum erythropoietin levels are not already elevated and transfusion needs are modest.
Granulocyte colony-stimulating factor (G-CSF): May be used to boost white blood cell counts during serious infections.

Disease-Modifying Treatments

For patients with higher-risk MDS or those whose disease is progressing:

Hypomethylating agents (HMAs): Azacitidine and decitabine are the most commonly used treatments for higher-risk MDS. They work by altering gene expression in abnormal bone marrow cells and can slow progression to AML, reduce transfusion dependence, and improve blood counts. These medicines require routine blood test monitoring throughout treatment.
Lenalidomide: Specifically effective for MDS with isolated del(5q). It can significantly reduce or eliminate transfusion dependence in this subtype.
Immunosuppressive therapy: In younger patients with lower-risk MDS, particularly those with certain features suggesting an immune-mediated component, antithymocyte globulin (ATG) with or without cyclosporine may be considered.

Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only treatment with the potential to cure MDS. It involves replacing the patient's diseased bone marrow with healthy donor stem cells. Only a small proportion of people with MDS are candidates for transplant, and the decision is highly individualized. HSCT is generally reserved for younger, medically fit patients with higher-risk disease due to the significant risks involved, including transplant-related complications and graft-versus-host disease (GVHD). The decision to pursue transplant requires careful specialist evaluation.

MDS and the Risk of Transformation to AML

One of the most important concerns in MDS is the risk of transformation to acute myeloid leukemia (AML). This occurs when the percentage of blast cells in the bone marrow rises to 20% or above.

Only a portion of people with MDS will ever develop AML — others live for many years with MDS as a chronic condition. The risk of transformation varies considerably by subtype:

Low-risk MDS: Transformation is uncommon and may occur over many years, if at all
High-risk MDS (excess blasts): Transformation risk is substantially higher and may occur within months to a few years without treatment

Regular monitoring of blood counts and bone marrow assessments is important for detecting signs of disease progression early.

Complications

The main complications of MDS arise from chronically low blood cell counts and, in higher-risk disease, from progression to AML:

Severe anemia requiring ongoing transfusions and potential iron overload
Life-threatening infections due to low white blood cell counts
Serious bleeding due to low platelet counts
Transformation to acute myeloid leukemia
Complications from treatment, including infection risk from immunosuppressive therapy or stem cell transplantation

Living With MDS

A diagnosis of MDS can be overwhelming, particularly because the condition varies so widely between individuals. For many people with low-risk disease, life can continue with relatively few disruptions, especially with good symptom management and regular monitoring.

Practical considerations include:

Attending all scheduled blood tests and specialist appointments — CBC monitoring is essential for tracking disease activity
Avoiding unnecessary infections where possible: washing hands frequently, staying current with vaccines as advised by your doctor, and seeking prompt treatment for any signs of infection
Avoiding aspirin and NSAIDs unless specifically recommended by your doctor, as these affect platelet function
Discussing fatigue management strategies with your care team, as anemia-related fatigue is one of the most common and disruptive symptoms
Asking your specialist which activities are safe at your current blood count levels
Connecting with a patient support organization such as the MDS Foundation or the Aplastic Anemia and MDS International Foundation (AAMDSIF), which offer resources, education, and peer support
Seeking referral to a hematologist or MDS specialist, particularly at a center with experience in bone marrow disorders, for diagnosis and ongoing management

Frequently Asked Questions About MDS

Is MDS a form of cancer?

MDS is classified as a hematologic (blood) cancer or pre-cancer. It arises from genetic mutations in bone marrow cells and, in higher-risk forms, can progress to acute myeloid leukemia. However, many low-risk cases behave more like a chronic condition and do not progress to leukemia during a patient's lifetime.

What is the life expectancy with MDS?

Prognosis varies enormously depending on the subtype and risk category. Low-risk MDS may have a median survival of several years or more; high-risk forms with excess blasts often have a shorter outlook without treatment. Individual outcomes depend on age, overall health, genetic features, and response to treatment. Your hematologist can provide a more personalized estimate based on your specific situation.

How is MDS different from leukemia?

In MDS, the bone marrow produces too few functional blood cells and contains less than 20% blast cells. When blast cells reach 20% or above, the condition is reclassified as AML. MDS can be thought of as existing on a spectrum that, in some patients, progresses toward leukemia over time.

How is MDS monitored over time?

Regular CBC testing is the cornerstone of MDS monitoring. Depending on the risk level, this may be every one to three months. Repeat bone marrow biopsies may be recommended if blood counts change significantly or if disease progression is suspected.

Can MDS be prevented?

Most cases cannot be clearly linked to a preventable cause, and MDS is not preventable in most people. Reducing exposure to known risk factors — such as benzene, industrial chemicals, and tobacco smoke — may lower risk in some circumstances. People who have received chemotherapy or radiation are monitored for therapy-related MDS as part of their long-term cancer follow-up.

What does MDS look like on a blood test?

Common CBC findings include low hemoglobin (anemia), low platelet count, low white blood cell count, elevated MCV (large red blood cells), and elevated RDW (variation in red blood cell size). MPV may be low, reflecting impaired platelet production. These findings together — especially in an older adult — may prompt referral for further evaluation including a bone marrow biopsy.

Related Biomarkers

The following blood test markers are relevant to the diagnosis and monitoring of MDS. Tracking these over time can help your doctor identify trends and assess treatment response:

Sources

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes. Lancet Oncology. 2009;10(3):223-232.
Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.
Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096-1107.
Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. Journal of Clinical Oncology. 2009;27(5):754-762.
List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. New England Journal of Medicine. 2006;355(14):1456-1465.

Article written by: HealthMatters.io Team, reviewed by: HealthMatters Editorial Team Last updated: April 2026